Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16014541 | 0.86 | GRM4 (0.41) | GRM4 | |
| SCHEMBL17403444 | 0.83 | FFAR1 (0.35) | — | |
| SCHEMBL16014806 | 0.83 | POLA1 (0.31) | — | |
| SCHEMBL16014775 | 0.80 | MEN1 (0.44) | GRM4 | |
| SCHEMBL16014596 | 0.79 | S1PR2 (0.37) | — | |
| SCHEMBL18856747 | 0.71 | HDAC3 (0.51) | GRM4APP | |
| SCHEMBL18856679 | 0.70 | CGAS (0.33) | GRM4 | |
| SCHEMBL18856842 | 0.69 | TDO2 (0.36) | GRM4TDO2 | |
| SCHEMBL18755089 | 0.69 | LMNA (0.35) | — | |
| SCHEMBL2297554 | 0.68 | LMNA (0.50) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964626-A1 | ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | claimed |
| US-20160002180-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (US) | 2016-01-07 | — | — | US | claimed |
| WO-2014135472-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | claimed |
| EP-2964626-A1 | ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002180-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002180-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002180-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2014135472-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002180-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | GRM4 4330/4885IDO1 535/4885TDO2 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.